Pournara E[au] - Search Results

Year	Number of Results
2016	3
2017	5
2019	1
2020	4
2021	4
2022	6
2023	5

1

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D'Angelo S, Schulz B, Rissler M, Nagar K, Perella C, Coates LC. Baraliakos X, et al. Among authors: pournara e. Ann Rheum Dis. 2021 May;80(5):582-590. doi: 10.1136/annrheumdis-2020-218808. Epub 2020 Dec 17. Ann Rheum Dis. 2021. PMID: 33334727 Free PMC article. Clinical Trial.

2

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review.

Gisondi P, Simon D, Alarcon I, Pournara E, Puig L. Gisondi P, et al. Among authors: pournara e. J Dermatolog Treat. 2023 Dec;34(1):2167487. doi: 10.1080/09546634.2023.2167487. J Dermatolog Treat. 2023. PMID: 36625506 Free article. Review.

3

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.

Ogdie A, Gladman DD, Coates LC, Pournara E, Parikh B, Mease PJ. Ogdie A, et al. Among authors: pournara e. Rheumatol Ther. 2023 Aug;10(4):849-860. doi: 10.1007/s40744-023-00548-y. Epub 2023 May 6. Rheumatol Ther. 2023. PMID: 37148474 Free PMC article.

4

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial.

Baraliakos X, Pournara E, Gossec L, Mease PJ, White R, O'Brien E, Schulz B, Marzo-Ortega H, Coates LC. Baraliakos X, et al. Among authors: pournara e. RMD Open. 2022 Jul;8(2):e002303. doi: 10.1136/rmdopen-2022-002303. RMD Open. 2022. PMID: 35850974 Free PMC article. Clinical Trial.

5

Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.

Reich K, Puig L, Szepietowski JC, Paul C, Lacour JP, Tsianakas A, Sieder C, Rissler M, Pournara E, Orsenigo R. Reich K, et al. Among authors: pournara e. Br J Dermatol. 2020 Feb;182(2):304-315. doi: 10.1111/bjd.18143. Epub 2019 Sep 8. Br J Dermatol. 2020. PMID: 31102257 Clinical Trial.

6

Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial.

Baraliakos X, Sewerin P, de Miguel E, Pournara E, Kleinmond C, Shekhawat A, Jentzsch C, Wiedon A, Behrens F; ACHILLES study group. Baraliakos X, et al. Among authors: pournara e. Arthritis Res Ther. 2022 May 16;24(1):111. doi: 10.1186/s13075-022-02797-8. Arthritis Res Ther. 2022. PMID: 35578245 Free PMC article. Clinical Trial.

7

Comment on: MRI characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort: Reply.

Baraliakos X, Pournara E, Coates LC, Navarro-Compán V, Blanco R, O'Brien E, Schulz B, Landewe R. Baraliakos X, et al. Among authors: pournara e. Rheumatology (Oxford). 2023 Aug 24:kead413. doi: 10.1093/rheumatology/kead413. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37616495 No abstract available.

8

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.

Reich K, Baraliakos X, Coates LC, Elewski B, Bao W, Kasparek T, Gaillez C, Pournara E, Aassi M, Perella C, Gottlieb AB. Reich K, et al. Among authors: pournara e. Br J Dermatol. 2022 Sep;187(3):438-441. doi: 10.1111/bjd.21233. Epub 2022 Jun 7. Br J Dermatol. 2022. PMID: 35257363 Clinical Trial.

9

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.

Pournara E, Kormaksson M, Nash P, Ritchlin CT, Kirkham BW, Ligozio G, Pricop L, Ogdie A, Coates LC, Schett G, McInnes IB. Pournara E, et al. RMD Open. 2021 Nov;7(3):e001845. doi: 10.1136/rmdopen-2021-001845. RMD Open. 2021. PMID: 34795065 Free PMC article. Clinical Trial.

10

Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort.

Baraliakos X, Pournara E, Coates LC, Navarro-Compán V, Blanco R, O'Brien E, Schulz B, Landewe R. Baraliakos X, et al. Among authors: pournara e. Rheumatology (Oxford). 2023 Apr 24:kead162. doi: 10.1093/rheumatology/kead162. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37094184

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

25 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year